According to Dr. Reddy's's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.68747. At the end of 2023 the company had a P/S ratio of 3.55.
Year | P/S ratio | Change |
---|---|---|
2023 | 3.55 | 22.79% |
2022 | 2.89 | -26.07% |
2021 | 3.91 | -16.48% |
2020 | 4.69 | 70.98% |
2019 | 2.74 | -4.55% |
2018 | 2.87 | 1.04% |
2017 | 2.84 | -18.93% |
2016 | 3.51 | 6.16% |
2015 | 3.30 | -10.72% |
2014 | 3.70 | 16.68% |
2013 | 3.17 | 7.07% |
2012 | 2.96 | 10.44% |
2011 | 2.68 | -32.84% |
2010 | 3.99 | 46.9% |
2009 | 2.72 | 135.8% |
2008 | 1.15 | -51.75% |
2007 | 2.39 | -2.14% |
2006 | 2.44 | -23.56% |
2005 | 3.19 | -7.27% |
2004 | 3.44 | -44.95% |
2003 | 6.26 | -9.86% |
2002 | 6.94 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Novartis NVS | 4.31 | 16.91% | ๐จ๐ญ Switzerland |
Pfizer PFE | 2.78 | -24.74% | ๐บ๐ธ USA |
Sanofi SNY | 2.41 | -34.72% | ๐ซ๐ท France |
GlaxoSmithKline GSK | 2.18 | -40.87% | ๐ฌ๐ง UK |
Teva Pharmaceutical Industries TEVA | 1.22 | -66.92% | ๐ฎ๐ฑ Israel |